Theratechnologies "announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company’s lead investigational peptide drug conjugate for the treatment of sortilin-expressing cancers. The Company plans to submit an amendment to its protocol to the U.S. Food and Drug Administration for approval. Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on THTX:
- Theratechnologies Nosedives on Pausing Phase 1 Trial
- Theratechnologies Announces Update from Ongoing TH1902 Study
- Theratechnologies initiated with a Buy at JonesTrading
- Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population